BlackRock Fund Advisors’s Agile Therapeutics AGRX Stock Holding History

BlackRock Fund Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.47M	Buy	217 +29	+15%	+$406K	﹤0.01%	3120
2016 Q3	$2.62M	Buy	188 +11	+6%	+$157K	﹤0.01%	3096
2016 Q2	$2.69M	Buy	177 +7	+4%	+$95.8K	﹤0.01%	3114
2016 Q1	$2.12M	Buy	170 +29	+21%	+$374K	﹤0.01%	3068
2015 Q4	$2.74M	Buy	141 +4	+3%	+$63.3K	﹤0.01%	3070
2015 Q3	$1.84M	Sell	137 -1	-0.7%	-$17.8K	﹤0.01%	3132
2015 Q2	$2.38M	Buy	138 +125	+962%	+$2.67M	﹤0.01%	3150
2015 Q1	$236K	Buy	13 +1	+8%	+$17.5K	﹤0.01%	3439
2014 Q4	$148K	Buy	12 +1	+9%	+$12.7K	﹤0.01%	3550
2014 Q3	$164K	Sell	11 -1	-8%	-$15.4K	﹤0.01%	3534
2014 Q2	$210K	Buy	+12	New	+$174K	﹤0.01%	3471

Other funds holding AGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Fund Advisors's AGRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Agile Therapeutics (AGRX) stake by 15% in Q4 2016, buying an estimated $406K and bringing the position to 217 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

BlackRock Fund Advisors first reported a position in AGRX in Q2 2014 and has held it in 11 quarters since. The position peaked at $2.74M in Q4 2015. 62 funds tracked by Wall St. Rank hold AGRX as of Q4 2016.

BlackRock Fund Advisors held 217 shares of Agile Therapeutics worth $2.47M as of Q4 2016.
BlackRock Fund Advisors bought 29 Agile Therapeutics shares in Q4 2016, an estimated $406K.
Agile Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3120 holding.
BlackRock Fund Advisors first reported a position in Agile Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Fund Advisors's Agile Therapeutics position peaked at $2.74M in Q4 2015.
62 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.